Results

Adding Tarlatamab to Durvalumab Maintenance Lifted Median Survival to 21.1 Months in Small Cell Lung Cancer

A phase 3 trial presented at ESMO and published in NEJM reports a 58 percent lower risk of death in extensive-stage disease, with frequent but mostly mild cytokine release syndrome.

Oct 27, 2026